ArticleCell death discovery2025
Tumor-derived exosomal tsRNA 3'tiRNA-AlaCGC in promoting fibroblast senescence and Galectin-9 secretion to induce immune tolerance in lung adenocarcinoma.
Article in Cell death discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Extracellular vesicles in senescence-associated chronic lung diseases.Chinese medical journal · 2026Review
- Immunological consequences of senescence in physiology and pathology.Journal of translational medicine · 2026Review
- Galectin-9Aging cell · 2026Article
- BMSC-derived extracellular vesicles affect gluconeogenesis and lipogenesis by releasing 5'-tRF-GlyCCC to improve MAFLD insulin sensitivity.Cell biology and toxicology · 2026Article
- Decoding the tumor-aging axis: from bench to clinical.Frontiers in immunology · 2026Review
- Transfer RNA expression, modification, and derived small RNAs in cancer biology and clinical potential.Frontiers in immunology · 2026Review
- Exo-nanomaterials in cancer immunotherapy: reprogramming the tumor immune microenvironment.Frontiers in immunology · 2025Review
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Given the heterogeneity of the tumor microenvironment (TME), neoadjuvant immunotherapy combined with chemotherapy benefits only a subset of lung adenocarcinoma (LUAD) patients, and the mechanisms of resistance remain unclear. Transfer RNA-derived small RNAs (tsRNAs) are a new class of non-coding RNAs that participate in the remodeling of the TME. Using high-throughput small RNA microarray analysis, we found elevated expression of tsRNA 3'tiRNA-AlaCGC in tumors of LUAD patients resistant to neoadjuvant therapy, and negatively correlated with the poor prognosis in LUAD patients. Furthermore, we discovered that tumor-derived exosome carrying 3'tiRNA-AlaCGC target fibroblasts to induce a senescence-associated secretory phenotype (SASP) by inhibiting FOXO3, and activating the TGF-β/Smad3 pathway, thereby increasing Galectin-9 secretion; both SASP and Galectin-9 induce synthetically dysfunction of cytotoxic CD8
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.